RENOVARO INC. (RENB) - Dilution Analysis

8-K filing: Stock split 1-for-8 | Outstanding: 22,520,245 → 2,815,030

8-K filing: Lunai Bioworks, Inc. exchanged debt for common stock and warrants, and entered into an agreement to acquire assets through a strategic investment. ($0.83M proceeds)

8-K filing: Lunai Bioworks Inc. entered into a securities purchase agreement to sell 3,133,333 shares of common stock at $1.00 per share and 1,044,444 warrants for gross proceeds of $3,133,333. ($3.13M proceeds)

10-Q filing | 22.5M shares outstanding

10-K filing | 231.8M shares outstanding

8-K filing: Stock split 1-for-10 | Outstanding: 163,930,470 → 23,178,096

8-K filing: Renovaro Inc. exchanged $9.7 million in secured promissory notes for $16.1 million in new convertible promissory notes, and subsequently issued 53.6 million shares of common stock upon conversion of the convertible notes at $0.30 per share.

10-Q filing | 163.9M shares outstanding

8-K filing: Renovaro, Inc. issued 15.0 million shares of its common stock to the former stockholders of Biosymetrics, Inc. in connection with the consummation of the Transaction on April 8, 2025.

8-K filing: Renovaro acquired 467,290 shares of Predictive Oncology's common stock for $500,000 and agreed to purchase an additional 901,298 shares for $964,389 upon the execution of a definitive agreement related to the proposed acquisition of Predictive Oncology by Renovaro. ($1.46M proceeds)

8-K filing: Renovaro, Inc. will issue 15 million shares of its common stock to the stockholders of Biosymetrics, Inc. as consideration for the merger, with 3 million shares held in escrow for one year.

10-Q filing | 161.8M shares outstanding

8-K filing: Renovaro Inc. entered into a binding letter of intent with Predictive Oncology Inc. for Predictive Oncology to be acquired by Renovaro in exchange for preferred stock of Renovaro. ($2.49M proceeds)

10-Q filing | 156.6M shares outstanding

S-3 filing: Renovaro Inc. files an S-3 form to offer common stock, warrants, or a combination of these securities, or units, up to a total offering price of $200,000,000.

10-K filing | 156.2M shares outstanding

8-K filing: Renovaro Inc. closed a private placement of 6,421,256 units, each consisting of one share of common stock and one warrant to purchase one-tenth of a share of common stock, for a combination of cash and the surrender of convertible promissory notes. ($6.35M proceeds)

10-Q filing | 147.5M shares outstanding

8-K filing: Renovaro Inc. reports the closing of a transaction triggering the conversion of Series A Convertible Preferred Stock into 5,610,100 shares of Common Stock, resulting in a total of 143,668,372 shares of Common Stock outstanding. The company also changed its name from 'Renovaro Biosciences Inc.' to 'Renovaro Inc.'

10-Q filing | 143.7M shares outstanding

10-Q filing | 64.5M shares outstanding

10-K filing | 65.7M shares outstanding

8-K filing: Renovaro Biosciences Inc. closed a private placement of units consisting of preferred stock and warrants, raising $2,000,000 in cash and converting $2,000,000 of promissory notes into additional units, and filed the Certificate of Designation for the Series A Convertible Preferred Stock. ($4.0M proceeds)

8-K filing: Enochian Biosciences Inc. closed a private placement of 2,454,382 shares of common stock and 1,227,191 warrants at $0.53 per share, for gross proceeds of $1,300,822, and also converted $1,200,000 of Amended and Restated Secured Notes into 2,264,150 shares of Common Stock and 1,132,075 Warrants. ($1.3M proceeds)

8-K filing: Enochian Biosciences Inc. entered into a purchase agreement with Lincoln Park Capital Fund, LLC, allowing the Company to sell up to $20,000,000 of its common stock over a 36-month term; the company issued 696,021 commitment shares to Lincoln Park as a fee.

10-Q filing | 58.3M shares outstanding

8-K filing: Enochian Biosciences Inc. closed a private placement of 2,178,070 shares of common stock and 1,089,036 common stock purchase warrants at a purchase price of $1.14 per share, for aggregate proceeds of $2,483,000. ($2.48M proceeds)

10-Q filing | 55.7M shares outstanding

10-Q filing | 55.7M shares outstanding

10-K filing | 55.7M shares outstanding

10-Q filing | 52.9M shares outstanding

S-3/A filing: Enochian BioSciences Inc. is offering shares of its common stock up to an aggregate amount of $100,000,000.

10-Q filing | 52.6M shares outstanding

S-3 filing: Enochian BioSciences Inc. may offer and sell shares of its common stock up to an aggregate amount of $100,000,000.

10-Q filing | 52.2M shares outstanding

10-K filing | 52.2M shares outstanding

8-K filing: Dr. Mark Dybul has been named Chief Executive Officer of Enochian Biosciences, Inc. and was awarded an option to purchase 3,000,000 shares of the Company's common stock.

8-K filing: Enochian Biosciences, Inc. entered into a securities purchase agreement to sell 3,866,668 shares of common stock in a registered direct offering for gross proceeds of approximately $29 million. ($29.0M proceeds)

10-Q filing | 47.8M shares outstanding

8-K filing: Enochian Biosciences, Inc. completed a private placement offering of 867,555 shares of its common stock at a purchase price of $3.92 per share, for aggregate proceeds to the Company of $3,400,800 on March 18, 2021. ($3.4M proceeds)

10-Q filing | 47.8M shares outstanding

10-Q filing | 46.6M shares outstanding

10-K filing | 46.6M shares outstanding

S-3/A filing: Enochian Biosciences, Inc. may offer and sell shares of its common stock up to an aggregate amount of $50,000,000 from time to time.

8-K filing: Enochian Biosciences Inc. entered into a purchase agreement with Lincoln Park Capital Fund, LLC, allowing the Company to sell up to $20,000,000 in shares of its common stock over a 36-month period.

S-3 filing: Enochian Biosciences, Inc. may offer and sell shares of its common stock up to an aggregate amount of $50,000,000 from time to time.

10-Q filing | 46.5M shares outstanding

10-Q filing | 46.3M shares outstanding